Nivolumab Followed by Ipilimumab Sequence Beneficial in Melanoma Treatment

Share this content:
Nivolumab followed by ipilimumab may be more clinically beneficial in contrast with the reverse sequence for treatment in patients with advanced melanoma.
Nivolumab followed by ipilimumab may be more clinically beneficial in contrast with the reverse sequence for treatment in patients with advanced melanoma.

Nivolumab followed by ipilimumab may be more clinically beneficial in contrast with the reverse sequence for treatment in patients with advanced melanoma, according to a study published in The Lancet Oncology.1

Researchers led by Jeffrey Weber, MD, of the New York University Langone Medical Center, conducted a randomized, open-label, phase 2 study of 140 patients who were randomly assigned to induction with intravenous nivolumab, followed by a planned switch to intravenous ipilimumab or the reverse sequence.

Primary endpoint was treatment-related grade 3 to 5 adverse events until week 25; secondary endpoints were “the proportion of patients who achieved a response at week 25 and disease progression at weeks 13 and 25.”

The researchers found that the proportion of patients with a response at week 25 was higher with nivolumab followed by ipilimumab than with the reverse sequence. Progression was found in 26 patients in the nivolumab followed by ipilimumab group, in contrast with 43 in the reverse sequence group at week 13; at week 25, progression was found in 26 patients in the former group and 42 in the latter.

The frequencies of treatment-related grade 3 to 5 adverse events up to week 25 were similar between the nivolumab followed by ipilimumab group and the reverse sequence group.

RELATED: Psychosocial, Demographic Factors Related to Worry in Patients With Melanoma Identified

With a median follow-up of 19.8 months, median overall survival was not reached in the nivolumab followed by ipilimumab group. Median overall survival was found to be 16.9 months in the ipilimumab followed by nivolumab group, with a median follow-up of 14.7 months.

It was found that a higher proportion of patients in the nivolumab followed by ipilumumab group achieved 12-month overall survival.

Reference

  1. Weber JS, Gibney G, Sullivan RJ, Sosman JA, Slingluff Jr CL, Lawrence DP, et al. Sequential administration of nivolumab and ipilimumab with a planned switch in patients with advanced melanoma (CheckMate 064): an open-label, randomised, phase 2 trial. [published online ahead of print June 4, 2016.] The Lancet Oncol. doi: 

Related Resources

You must be a registered member of Cancer Therapy Advisor to post a comment.

Regimen and Drug Listings

GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION

Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Prostate Cancer Regimens Drugs
Rare Cancers Regimens
Renal Cell Carcinoma Regimens Drugs
Skin Cancer Regimens Drugs
Urologic Cancers Regimens Drugs

Sign Up for Free e-newsletters